2020.Jun.10
OBI filled application of Phase 1 human clinical study for Novel Botulinum Toxin preparation, OBI-858, to TFDA
OBI filled application of Phase 1 human clinical study for Novel Botulinum Toxin preparation, OBI-858, to TFDA Date of occurrence of the event: Jun 10, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not applicable Cause of occurrence: OBI filled application of […]
This article is password protected.
To view the content, please enter your password in the field below